Overview

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Status:
Completed

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

This pilot clinical trial studies how well desipramine hydrochloride and filgrastim works for stem cell mobilization in patients with multiple myeloma undergoing stem cell transplant. Giving colony-stimulating factors, such as filgrastim, and other drugs, such as desipramine hydrochloride, helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.

Phase:

N/A

Details

Lead Sponsor:

Albert Einstein College of Medicine
Albert Einstein College of Medicine of Yeshiva University

Collaborator:

National Cancer Institute (NCI)

Treatments:

Desipramine
Lenograstim